- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 12.12.24 | Corcept's cortisol modulator fails to slow ALS decline, linked to 'gastrointestinal upset' at onset | ||
| 12.12.24 | Multiomics startup Pleno raises $25M for commercial launch, plucks new CEO from Illumina | ||
| 12.12.24 | Keros' stock tanks after halting 2 arms of hypertension trial over fluid buildups around heart | ||
| 12.12.24 | Industry M&A volume declined 8% this year compared to '23: PwC | ||
| 11.12.24 | Bavarian Nordic plans to shut down San Diego R&D site, lay off 48 employees | ||
| 11.12.24 | Reverse, reverse: Liver disease biotech Hepion and Pharma Two B call off merger | ||
| 11.12.24 | USPSTF endorses HPV self-collection tests for cervical cancer screening | ||
| 11.12.24 | AnaptysBio scraps atopic dermatitis asset after antibody fails to meet all endpoints in ph. 2 | ||
| 11.12.24 | Jury convicts ex-CytoDyn CEO on 9 counts tied to biotech fraud | ||
| 11.12.24 | Candel burns bright as phase 3 prostate cancer win sends stock up 200% | ||
| 11.12.24 | Angitia raises $120M series C to fund trio of musculoskeletal trials | ||
| 11.12.24 | Capstan Medical collects $110M for robotic heart valve replacements | ||
| 11.12.24 | Q32's stock plunges in wake of phase 2 eczema fail for anti-IL-7R antibody | ||
| 11.12.24 | 2 Boston-area biotechs shed staff, fuse to form genetic medicines company nChroma Bio | ||
| 11.12.24 | BenevolentAI pivots back to 'TechBio' roots, causing more layoffs | ||
| 11.12.24 | Cellectar lays off 60% of staff, ditches lead radiotherapy over FDA demand for another trial | ||
| 11.12.24 | Spruce saws off only drug after 2nd hyperplasia fail, leaving biotech's direction in doubt | ||
| 10.12.24 | In midstage colorectal cancer trial, Cardiff's KRAS candidate linked to 64% response rate at higher dose | ||
| 10.12.24 | Artivion nets FDA humanitarian green light for prosthetic aortic tear implant | ||
| 10.12.24 | Roche said it didn't want to buy Poseida last year: A look at how the $1.5B buyout came to be | ||
| 10.12.24 | FDA clears AngioDynamics' NanoKnife pulsed field ablation system for prostate cancer | ||
| 10.12.24 | Lava burnt by blood cancer drug's performance in phase 1, pivots to preclinical backup | ||
| 10.12.24 | BioNTech's overall survival data show promise of potential Keytruda killer in breast cancer | ||
| 10.12.24 | NewAmsterdam's stock rises on early sign cholesterol drug improves cardiovascular outcomes | ||
| 10.12.24 | CervoMed's ex-Vertex drug fails to reduce dementia symptoms in phase 2 trial |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
